MX2022003018A - Danavorexton (tak-925) para usarse en el tratamiento de la narcolepsia. - Google Patents
Danavorexton (tak-925) para usarse en el tratamiento de la narcolepsia.Info
- Publication number
- MX2022003018A MX2022003018A MX2022003018A MX2022003018A MX2022003018A MX 2022003018 A MX2022003018 A MX 2022003018A MX 2022003018 A MX2022003018 A MX 2022003018A MX 2022003018 A MX2022003018 A MX 2022003018A MX 2022003018 A MX2022003018 A MX 2022003018A
- Authority
- MX
- Mexico
- Prior art keywords
- treating narcolepsy
- tak
- compound
- methyl
- subject
- Prior art date
Links
- UXZAJSZFFARTEI-YRPNKDGESA-N CS(=O)(=O)N[C@@H]1[C@@H](N(CCC1)C(=O)OC)CO[C@@H]1CC[C@@H](CC1)C1=CC=CC=C1 Chemical compound CS(=O)(=O)N[C@@H]1[C@@H](N(CCC1)C(=O)OC)CO[C@@H]1CC[C@@H](CC1)C1=CC=CC=C1 UXZAJSZFFARTEI-YRPNKDGESA-N 0.000 title 1
- 201000003631 narcolepsy Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000035959 Narcolepsy type 1 Diseases 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 208000004461 narcolepsy 1 Diseases 0.000 abstract 2
- -1 (4-phenylcyclohexyl)oxy Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000036470 plasma concentration Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962900298P | 2019-09-13 | 2019-09-13 | |
| US202063031686P | 2020-05-29 | 2020-05-29 | |
| PCT/IB2020/058483 WO2021048822A1 (en) | 2019-09-13 | 2020-09-12 | Tak-925 for use in treating narcolepsy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022003018A true MX2022003018A (es) | 2022-06-14 |
Family
ID=72560858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022003018A MX2022003018A (es) | 2019-09-13 | 2020-09-12 | Danavorexton (tak-925) para usarse en el tratamiento de la narcolepsia. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220339143A1 (https=) |
| EP (1) | EP4028004A1 (https=) |
| JP (1) | JP2022547711A (https=) |
| KR (1) | KR20220062012A (https=) |
| CN (1) | CN114980892A (https=) |
| AU (1) | AU2020346456A1 (https=) |
| BR (1) | BR112022004587A2 (https=) |
| CA (1) | CA3154321A1 (https=) |
| CO (1) | CO2022004596A2 (https=) |
| MX (1) | MX2022003018A (https=) |
| WO (1) | WO2021048822A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022004576A2 (pt) * | 2019-09-13 | 2022-06-14 | Takeda Pharmaceuticals Co | Métodos para diminuir ou tratar sonolência excessiva, tratar narcolepsia tipo 2 ou hipersonia idiopática, tratar distúrbio de trabalho de turno, aumentar latência de sono em manutenção de teste de insônia, melhorar classificação de escaça de sonolência de karolinska, diminuir ou melhorar sonolência subjetiva, aumentar insônia ou diminuir sonolência excessiva, melhorar classificação de escala de sonolência epworth, tratar narcolepsia tipo 2, diminuir ou tratar sonolência diurna excessiva, e, composição farmacêutica |
| MX2022008392A (es) | 2020-01-10 | 2022-08-08 | Takeda Pharmaceuticals Co | Metodo para mejorar la farmacocinetica o aumentar la concentracion de plasma de 3-((metilsulfonil)amino)-2-(((4-fenilci clohexil)oxi)metil)piperidina-1-carboxilato de metilo o una sal del mismo con un inhibidor de citocromo p450. |
| US12503475B2 (en) | 2020-09-03 | 2025-12-23 | Centessa Pharmaceuticals (Uk) Limited | Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists |
| BR112023020104A2 (pt) * | 2021-04-02 | 2023-11-14 | Takeda Pharmaceuticals Co | Métodos para recuperação pós-operação, para facilitar a recuperação ou reduzir o tempo de recuperação da anestesia, para prevenir ou tratar distúrbios/depressão respiratória pós-operatória ou distúrbios/depressão respiratória induzida por opioides, sedação pós-operatória ou sedação induzida por opioides e para reduzir um efeito colateral de opioides |
| CN119677753A (zh) | 2022-04-22 | 2025-03-21 | 帝人制药株式会社 | 氧杂氮杂环庚三烯衍生物 |
| AR130709A1 (es) | 2022-10-07 | 2025-01-08 | Kissei Pharmaceutical | Compuesto de ciclopentano |
| WO2024095158A1 (en) * | 2022-10-31 | 2024-05-10 | Takeda Pharmaceutical Company Limited | Dosing of orexin type 2 receptor agonists |
| TW202535890A (zh) | 2023-10-20 | 2025-09-16 | 日商帝人製藥股份有限公司 | 氧氮呯衍生物之結晶或其溶劑合物之結晶 |
| WO2025124698A1 (en) | 2023-12-12 | 2025-06-19 | Idorsia Pharmaceuticals Ltd | Aryl sulfone and sulfanone derivatives as orexin receptor modulators |
| TW202542165A (zh) | 2023-12-19 | 2025-11-01 | 瑞士商愛杜西亞製藥有限公司 | 大環食慾素激動劑 |
| WO2025229493A1 (en) * | 2024-04-29 | 2025-11-06 | Takeda Pharmaceutical Company Limited | Dosing of orexin type 2 receptor agonists |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5854204A (en) | 1995-03-14 | 1998-12-29 | Praecis Pharmaceuticals, Inc. | Aβ peptides that modulate β-amyloid aggregation |
| JP2001500852A (ja) | 1996-08-27 | 2001-01-23 | プレーシス ファーマスーティカルズ インコーポレイテッド | Ｄ―アミノ酸を含むβ―アミロイドペプチド凝集のモジュレーター |
| CA2374610A1 (en) | 1999-06-28 | 2001-01-04 | Jordan J. N. Tang | Catalytically active recombinant memapsin and methods of use thereof |
| ES2843952T3 (es) * | 2014-10-23 | 2021-07-21 | Eisai R&D Man Co Ltd | Composiciones para tratar el insomnio |
| US10022355B2 (en) * | 2015-06-12 | 2018-07-17 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder |
| PL3411358T3 (pl) * | 2016-02-04 | 2022-02-28 | Takeda Pharmaceutical Company Limited | Podstawiony związek piperydynowy i jego zastosowanie |
-
2020
- 2020-09-12 CA CA3154321A patent/CA3154321A1/en active Pending
- 2020-09-12 JP JP2022516270A patent/JP2022547711A/ja active Pending
- 2020-09-12 WO PCT/IB2020/058483 patent/WO2021048822A1/en not_active Ceased
- 2020-09-12 CN CN202080073637.7A patent/CN114980892A/zh active Pending
- 2020-09-12 BR BR112022004587A patent/BR112022004587A2/pt unknown
- 2020-09-12 AU AU2020346456A patent/AU2020346456A1/en not_active Abandoned
- 2020-09-12 KR KR1020227011013A patent/KR20220062012A/ko active Pending
- 2020-09-12 EP EP20775077.9A patent/EP4028004A1/en not_active Withdrawn
- 2020-09-12 MX MX2022003018A patent/MX2022003018A/es unknown
- 2020-09-12 US US17/642,331 patent/US20220339143A1/en not_active Abandoned
-
2022
- 2022-04-11 CO CONC2022/0004596A patent/CO2022004596A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022004587A2 (pt) | 2022-06-14 |
| KR20220062012A (ko) | 2022-05-13 |
| CN114980892A (zh) | 2022-08-30 |
| US20220339143A1 (en) | 2022-10-27 |
| WO2021048822A1 (en) | 2021-03-18 |
| CO2022004596A2 (es) | 2022-08-30 |
| AU2020346456A1 (en) | 2022-04-14 |
| CA3154321A1 (en) | 2021-03-18 |
| EP4028004A1 (en) | 2022-07-20 |
| JP2022547711A (ja) | 2022-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022003018A (es) | Danavorexton (tak-925) para usarse en el tratamiento de la narcolepsia. | |
| ZA202200519B (en) | Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents | |
| CR20220609A (es) | Antagonistas del receptor de lpa y usos de los mismos | |
| WO2019143902A3 (en) | Substituted heterocycles as antiviral agents | |
| AU2020231934A8 (en) | Compounds useful in HIV therapy | |
| BR112013020620A2 (pt) | análogos de ácido 4-hidroxibutírico | |
| MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| NO20076425L (no) | Fremgangsmater for behandling av drug-resistent cancer | |
| GEAP202516802A (en) | Protac chimeric compound, preparation method thereof and use thereof | |
| MX2025009374A (es) | Compuesto que contiene trifluorometilsulfonilo | |
| PH12020551117A1 (en) | Compositions for preventing or treating uveitis | |
| MX2024002131A (es) | Inhibidores de la 17-beta-hidroxisteroide deshidrogenasa tipo 13 y metodos de uso de los mismos. | |
| PH12022551241A1 (en) | Egfr inhibitors | |
| MY198008A (en) | Crystal of benzofuran derivative free base and preparation method | |
| CA3139148A1 (en) | Crystalline salt forms of a kinase inhibitor | |
| PH12022552495A1 (en) | Oxazolidinone compound and methods of use thereof as an antibacterial agent | |
| MX2024012882A (es) | Compuestos de liberacion de gamma-hidroxibutirato y procesos para fabricar y usar los mismos | |
| MX2025009098A (es) | Sal y forma cristalina de un compuesto cicloalquenico y metodo de preparacion de estos y uso de estos | |
| MX2024015882A (es) | Derivados de 3-(sulfonil o sulfonimidoil)prop-2-en-1-il]-2-oxo-1,2-dihidropiridina-3-carboxamida | |
| PH12021552349A1 (en) | Biomarkers for selinexor | |
| MX2025013372A (es) | Inhibidores de gsk3\03b1 y metodos de uso de estos | |
| ZA202206588B (en) | Metal salts and uses thereof | |
| MX2024012970A (es) | Inhibidores de la 17-beta-hidroxiesteroide deshidrogenasa tipo 13 que contienen pirimidinona | |
| PE20220391A1 (es) | Compuestos para el tratamiento de trastornos neuromusculares | |
| MX2022001413A (es) | Compuesto de pirimidina-5-carboxamida. |